Maxigen Biotech Inc. vs Stereotaxis, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Stereotaxis, Inc. is the larger company by market value: $92 M against $87 M for Maxigen Biotech Inc., 1.1 times as much (market caps of Nov 20, 2026 for Maxigen Biotech Inc. and Oct 30, 2026 for Stereotaxis, Inc.).
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Maxigen Biotech Inc. 1783.TW · #19,241 in the world | Stereotaxis, Inc. STXS · #19,021 in the world |
|---|---|---|
| Profile | ||
| Country | 🇹🇼 Taiwan | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments | Medical Instruments |
| Founded | — | 1990 |
| Size | ||
| Market cap | $87 M | $92 M |
| Revenue | — | $32 M |
| Net income | — | $-22 M |
| Employees | — | 131 |
| Valuation | ||
| Price to sales | — | 2.9× |
| Price to book | — | 6.8× |
| Free cash flow yield | — | -15.0% |
| Profitability | ||
| Gross margin | — | 52.7% |
| Operating margin | — | -68.3% |
| Net margin | — | -66.8% |
| Return on equity | — | -221.3% |
| Growth | ||
| Revenue growth | — | 20.3% |
| Revenue growth, 3 years a year | — | 4.8% |
| Cash | ||
| Free cash flow margin | — | -42.5% |
| Shareholder returns | ||
| Dividend yield | — | 0.0% |
| Shareholder yield | — | 0.0% |
| Altman Z-score zone | — | distress |
| Data as of | Market cap Nov 2026 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Maxigen Biotech Inc. or Stereotaxis, Inc.?
Stereotaxis, Inc. is the larger company by market value: $92 M against $87 M for Maxigen Biotech Inc., 1.1 times as much (market caps of Nov 20, 2026 for Maxigen Biotech Inc. and Oct 30, 2026 for Stereotaxis, Inc.).